HIV 1 News and Research

RSS

Study shows how HIV protein permanently alters immune cells

Though antiretroviral therapy has made HIV a manageable disease, people living with HIV often suffer from chronic inflammation.

22 Nov 2022

The biological properties of the SARS-CoV-2 E protein in the context of HIV-1

Researchers assessed the effectiveness of SARS-CoV and SARS-CoV-2 envelope proteins against HIV-1.

22 Nov 2022

β-cyclodextrin family found to be promising and cost-effective antiviral agents against SARS-CoV-2

Researchers identified β-cyclodextrins (β-CDs) as a safe and cost-effective drug against SARS-CoV-2 with a broad spectrum of activity.

18 Nov 2022

Researchers provide new insights into the vexing process that makes HIV stealthy

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.

14 Nov 2022

Researchers take a cue from viruses to make glioblastoma more vulnerable to treatment

In the tough war against glioblastoma, scientists are taking a cue from viruses on how to make the aggressive cancer more vulnerable to treatment.

1 Nov 2022

What is the impact of SARS-CoV-2 on HIV-1 infectivity?

In a new study, researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV envelope (E) proteins on human immunodeficiency virus type 1 (HIV-1) infectivity.

31 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

The AIDS Clinical Trials Group (ACTG), the world's largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, today presented a session demonstrating that a three-dose regimen of the HEPLISAV-B vaccine fully protected people living with HIV at IDWeek 2022, taking place in Washington D.C. from October 19-22, 2022.

20 Oct 2022

Danish researchers take an important step in finding a cure for HIV

For around 40 years, scientists all over the world have been unsuccessfully trying to find a cure for HIV, but now a team of researchers from Aarhus University and Aarhus University Hospital have apparently found an important element in the equation.

17 Oct 2022

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

The involvement of minor intron-containing gene-encoded proteins in viral infections

Researchers explored the role of the minor intron-containing gene (MIG)-encoded proteins (MIG-Ps) depending on minor spliceosome-MiG excision to be expressed in infections by pathogenic viruses.

6 Oct 2022

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

Natural product SSP derived from a Chinese herb may have broad antiviral activities against respiratory viral infections

A research team comprised of members of the School of Chinese Medicine, AIDS Institute, Department of Microbiology, School of Clinical Medicine and State Key Laboratory for Emerging Infectious Diseases, the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have discovered a natural product SSP derived from a Chinese herb Spatholobus Suberectus Dunnthat demonstrated broad antiviral activities against SARS-CoV-1, SARS-CoV-2, influenza, and HIV-1 as an entry blocker.

27 Sep 2022

Study demonstrates how pan-sarbecovirus ORF7a protein plays a role in evading host immunity

In a new study, researchers demonstrated how sarbecovirus family down-regulates major histocompatibility complex-I (MHC-I) surface expression to evade cellular immunity.

26 Sep 2022

Synthetic mucin gels against HIV-1 and HSV-2 transmission

In a new study, researchers assessed the effectiveness of synthetic mucin gels in the inhibition of human immunodeficiency virus-1 (HIV-1) and herpes simplex virus-2 (HSV-2) Transmission.

21 Sep 2022

Monkeypox infection in a smallpox-vaccinated patient

In a recent study published in the Emerging Infectious Diseases journal, researchers at Madigan Army Medical Center assessed the characteristics of monkeypox infection in a patient vaccinated against smallpox.

20 Sep 2022

Monkeypox virus infection in an immunocompromised patient

Researchers assessed the manifestations of the monkeypox infection in an immunocompromised patient.

19 Sep 2022

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine, has received a four-year, $7.2 million grant from the NIH's National Institute of Child Health and Human Development renewing support for a Contraceptive Research Center at BUSM to further her research to develop innovative monoclonal antibody (mAb)-based contraceptive and multipurpose prevention technology (MPT) products.

15 Sep 2022

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

1 Sep 2022

Novel mechanism identified that SARS-CoV-2 uses to suppress antiviral responses to make the cell more permissive to infection

Researchers assessed the impact of SARS-CoV-2 ORF-6 on innate immune signaling.

30 Aug 2022